Antipsychotic combinations for schizophrenia

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 6, 2017, Pages

  Ortiz Orendain, Javier ^a   Castiello de Obeso, Santiago ^a   Colunga Lozano, Luis Enrique ^b   Hu, Yue ^c   Maayan, Nicola ^d   Adams, Clive E ^e  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

^b Reumatóloga adscrita al servicio de Reumatología Hospital Ángeles del Carmen   (Mexico)

^c TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d Graduate School ^*  (United Kingdom)

^e UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; PIPOTIAZINE; RESERPINE; RISPERIDONE; SERTINDOLE; SULPIRIDE;

AGRANULOCYTOSIS; ATAXIA; CLINICAL OUTCOME; DIPLOPIA; DROWSINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; HOSPITAL ADMISSION; HUMAN; HYPERPROLACTINEMIA; META ANALYSIS; MONOTHERAPY; NYSTAGMUS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SIDE EFFECT; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TREMOR; WEIGHT GAIN; COMBINATION DRUG THERAPY; PATIENT DROPOUT; RECURRENT DISEASE; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG THERAPY, COMBINATION; HUMANS; PATIENT DROPOUTS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 85021775314     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009005.pub2     Document Type: Review

References (243)

1. Essock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. American Journal of Psychiatry 2011;168(7):702-8. [DOI: 10.1176/appi.ajp.2011.10060908]5772249
2. Fricchione Parise V, Balletta G, Addeo L, Manna G. Effectiveness of antipsychotic polypharmacy or monotherapy: real-world study outcomes. European Neuropsychopharmacology 2012;22(Suppl 2):323. [DOI: 10.1016/S0924-977X(12)70495-9]5772251
3. Constantine RJ, Andel R, McPherson M, Tandon R. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial. Schizophrenia Research 2015;166(1-3):194-200. [DOI: 10.1016/j.schres.2015.05.038]5772253
4. Nishikawa T, Tsuda A, Tanaka M, Koga I, Uchida Y. Prophylactic effects of neuroleptics in symptom-free schizophrenics: roles of dopaminergic and noradrenergic blockers. Biological Psychiatry 1985;20(11):1161-6. [0006-3223: (Print); Nishikawa 1985]5772255
5. Barrett WW, Ellsworth RB, Clark LD, Enniss J. Study of the differential behavioral effects of reserpine, chlorpromazine, and a combination of these drugs in chronic schizophrenic patients. Diseases of the Nervous System 1957; Vol. 18, issue 6:209-15. [0012-3714: (Print); Barrett 1957]5772257
6. Wang CH, Qin TF, Lin YL, Zhao XF. A clinical effect and following-up study about sulpiride and clozapine for 105 cases of the schizophrenia type. Journal of Xinxiang Medical College 1994;11(2):148-51. [MK_007527]5772259
7. Talbot DR. Are tranquilizer combinations more effective than a single tranquilizer?. American Journal of Psychiatry 1964;121:597-600. [0002-953X: (Print); MEDLINE: Talbot 1964]5772261
8. Hori H, Yoshimura R, Katsuki A, Sugita AI, Atake K, Nakamura J. Switching to antipsychotic monotherapy can improve attention and processing speed, and social activity in chronic schizophrenia patients. Journal of Psychiatric Research 2013;47(12):1843-8. [DOI: 10.1016/j.jpsychires.2013.08.024]5772263
9. Fleischhacker WW, Heikkinen ME, Olie JP, Landsberg W, Dewaele P, McQuade RD, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine:a randomized, double-blind, placebo-controlled trial. International Journal of Neuropsychopharmacology 2010;13(8):1115-25. [DOI: 10.1017/S1461145710000490]5772266
10. Fleischhacker WW, Heikkinen ME, Olié JP, Landsberg W, Dewaele P, McQuade R, et al. Weight change on aripiprazole-clozapine combination in schizophrenic patients with weight gain and suboptimal response on clozapine: 16-week double-blind study. European Psychiatry 2008;23(Suppl 2):114-5. [DOI: 10.1016/j.eurpsy.2008.01.784; 0924-9338]5772265
11. Kriel W. A multicenter, comparative, randomized, double-blind, placebo controlled study on the effect on weight of adjunctive treatment with aripiprazole in patients with schizophrenia. www.sanctr.gov.za/SAClinicalTrials/tabid/169/Default.aspx (first received 15 November 2006). 5772267
12. Millar H, Felter C, Landsberg W. The effects of aripiprazole in combination with clozapine: patient functioning results from a double-blind, 16-week study in patients with schizophrenia (CN138-170). Journal of Psychopharmacology 2008;22(5):A17. [MEDLINE: Millar 2008 a]5772268
13. Muscatello MRA, Bruno A, Pandolfo G, Mico U, Scimeca G, Di Nardo F, et al. Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind-placebo-controlled study. Schizophrenia Research 2011;127(1-3):93-9. [DOI: 10.1016/j.schres.2010.12.011]5772270
14. Zhu H, Deng D. A study of clozapine combined with or without pipotiazine palmitate in refractory schizophrenia. Journal of Clinical Psychological Medicine 2002;12:15-7. 5772272
15. Kane JM, Correll CU, Goff DC, Kirkpatrick B, Marder SR, Vester-Blokland E, et al. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. Journal of Clinical Psychiatry 2009;70(10):1348-57. [1555-2101: (Electronic); DOI: 10.4088/JCP.09m05154yel; Kane 2009]5772274
16. NCT00325689. A multicenter, randomized, double-blind, placebo-controlled, 16 week study of aripiprazole used as dual therapy in the treatment of patients with chronic stable schizophrenia or schizoaffective disorder. www.clinicaltrials.gov/ct2/show/NCT00325689?term=NCT00325689&rank=1 (first received May 11 2006). [MEDLINE: Bristol-Myers 2006]5772275
17. Richardson CM, Feldman S, Kelly DL, Ball MP, Boggs DL, Weiner E, et al. Metabolic side effects of combined antipsychotic treatment: results from a double blind trial of adjunctive risperidone in clozapine treated people with treatment-resistant schizophrenia. Schizophrenia Bulletin 2009;35(Suppl 1):38-9. [MEDLINE: Richardson 2009]5772277
18. Weiner E, Conley RR, Ball MP, Feldman S, Gold JM, Kelly DL, et al. Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology 2010;35(11):2274-83. [DOI: 10.1038/npp.2010.101]5772278
19. Liu QH, Li XL, Zhang YQ, Jin SL, Li ZC, Wang NS, et al. A control study of clozapine in combination with sulpiride in alleviating the negative symptoms of schizophrenia. Chinese Journal of Psychiatry 1996;29(2):87-90. [MEDLINE: Liu 1996]5772280
20. Muscatello MR, Pandolfo G, Mico U, Lamberti Castronuovo E, Abenavoli E, Scimeca G, et al. Augmentation of clozapine with ziprasidone in refractory schizophrenia: a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology 2014;34(1):129-33. [DOI: 10.1097/JCP.0000000000000042]5772282
21. Assion HJ, Reinbold H, Lemanski S, Basilowski M, Juckel G. Amisulpiride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry 2008;41(1):24-8. [0176-3679: (Print); DOI: 10.1055/s-2007-993209; Assion 2008]5772284
22. Mayabhate M, Badar V, Somani A. Cognitive and psychomotor effects of adjunctive aripiprazole or paliperidone in patients of schizophrenia receiving olanzapine: a double-blind placebo controlled clinical study. International Journal of Basic and Clinical Pharmacology 2014;3(1):130-8. [DOI: 10.5455/2319-2003.ijbcp20140216]5772286
23. Chen HZ, Yu BR, Yang SG, Shen ZX, Mi Q, Jiang YH. Effect of aripiprazole on the hyperprolactinemia caused by sulpiride in the treatment of patients with schizophrenia: a clinical observation. Herald of Medicine 2007;26(10):1145-6. [Chen 2007]5772288
24. Shim J, Shin J, Kelly DL, Jung D, Seo Y, Conley RR. Adjunctive treatment with aripiprazole for haloperidol induced hyperprolactinemia: double blind, placebo controlled study. Schizophrenia Bulletin 2007;33:460. [Shim 2006 a]5772290
25. Shim JC, Jae YM, Shin JG, Jung DW, Seo YS, Liu KH, et al. Drug interactions between aripiprazole and haloperidol: double blind placebo controlled study. European Neuropsychopharmacology 2007;17:S438. [Shim 2007 d]5772291
26. Shim JC, Shin JG, Kelly DL, Jung DU, Seo YS, Liu KH, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. American Journal of Psychiatry 2007;164(9):1404-10. [0002-953X: (Print); DOI: 10.1176/appi.ajp.2007.06071075; Shim 2006 a1]5772292
27. Chang JS, Ahn YM, Park HJ, Lee KY, Kim SH, Kang UG, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. Asian Psychiatric Educational Workshop 2007;5:720-31. [MEDLINE: Chang 2008]5772294
28. Chang JS, Ahn YM, Park HJ, Lee KY, Kim SH, Kang UG, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry 2008;69(5):720-31. [1555-2101: (Electronic); MEDLINE: Kim 2006 g2]5772295
29. Chang JS, Lee NY, Ahn YM, Kim YS. The sustained effects of aripiprazole-augmented clozapine treatment on the psychotic systems and metabolic profiles of patients with refractory schizophrenia. Journal of Clinical Psychopharmacology 2012;32(2):282-4. [DOI: 10.1097/JCP.0b013e3182485871]5772296
30. Kim YS. A double-blind randomized placebo controlled study of aripiprazole augmentation for clozapine-treated patients with refractory schizophrenia. www.clinicaltrials.gov/ct2/show/NCT00328367?term=NCT00328367&rank=1 (first received 17 May 2006). [MEDLINE: Kim 2006 g]5772297
31. Jin JF, Chao YQ, Xu L, Song ZY, et al. Combined low-dose aripiprazole improved due to hyperprolactinemia chlorpromazine clinical study Journal of Psychiatry 2008;21(6):455-6. 5772299
32. Wang L, Zhang B, Xu L, et al. A clinical study on aripiprazole in the treatment of female hyperprolactinemia by haloperidol. China Journal of Health Psychology 2009;17(2):194-5. 5772301
33. Yasui-Furukori N, Kaneda A, Sugawara N, Tomita T, Kaneko S. Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients. Journal of Psychopharmacology 2012;26(6):806-12. [DOI: 10.1177/0269881111405555]5772303
34. Fan X, Borba CP, Copeland P, Hayden D, Freudenreich O, Goff DC, et al. Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. Acta Psychiatrica Scandinavica 2013;127(3):217-26. [DOI: 10.1111/acps.12009]5772305
35. Lee BJ, Lee SJ, Kim MK, Lee JG, Park SW, Kim GM, et al. Effect of aripiprazole on cognitive function and hyperprolactinemia in patients with schizophrenia treated with risperidone. Clinical Psychopharmacology and Neuroscience 2013; Vol. 11, issue 2:60-6. [DOI: 10.9758/cpn.2013.11.2.60]5772307
36. Chen JX, Zhang RZ, Li W, Liu YH, Jiang LY, Bian QT, et al. Adjunctive treatment of risperidone-induced hyperprolactinemia with aripiprazole: a randomized, double-blind, placebo-controlled study. Chinese Journal of New Drugs 2014; Vol. 23:811-4. 5772309
37. Chen JX, Su YA, Bian QT, Wei LH, Zhang RZ, Liu YH, et al. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: a randomized, double-blind, placebo-controlled, dose-response study. Psychoneuroendocrinology 2015;58:130-40. [DOI: 10.1016/j.psyneuen.2015.04.011]5772311
38. Raghuthaman G, Venkateswaran R, Krishnadas R. Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial. British Journal of Psychiatry Open 2015;1(2):172-7. [DOI: 10.1192/bjpo.bp.115.001248]5772313
39. ChiCTR-IOR-15006278. Adjunctive aripiprazole treatment for risperidone-induced hyperprolactinemia: an 8-week randomized, open-label, comparative clinical trial. www.chictr.org.cn/showprojen.aspx?proj=10830 (first received 22 April 2015). 5772315
40. Zhao J, Song X, Ai X, Gu X, Huang G, Li X, et al. Adjunctive aripiprazole treatment for risperidone-induced hyperprolactinemia: an 8-week randomized, open-label, comparative clinical trial. PLoS One 2015;10(10):e0139717. [DOI: 10.1371/journal.pone.0139717]5772316
41. ChiCTR-TRC-14004186. Research of the variance on patients with schizophrenia treated with aripiprazole on hyperprolactinemia induced by risperidone or paliperidone. www.chictr.org.cn/showprojen.aspx?proj=5382. China, (first received 8 January 2014). 5772318
42. Qiao Y, Yang F, Li C, Guo Q, Wen H, Zhu S, et al. Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone. Psychiatry Research 2016;237:83-9. [DOI: 10.1016/j.psychres.2015.12.033]5772319
43. Xie C, Ni XL. The compared study of treating schizophrenia with risperidone combining clozapine. Journal of Preventative Medicine 2001;17(4):245. [MEDLINE: Xie 2001]5772321
44. Jiang L, Lei J, Peng L, et al. Analysis of efficacy of antipsychotics combined with clozapine orally disintegrating tablets in the treatment of schizophrenia with negative symptoms Journal of Bethune Military Medical College 2013;11(4):310-11. 5772323
45. Chien CP, Cole JO. Depot phenothiazine treatment in acute psychosis: a sequential comparative clinical study. American Journal of Psychiatry 1973;130(1):13-8. [0002-953X: (Print); DOI: 10.1176/ajp.130.1.13; MEDLINE: Chien 1973]5772325
46. Potter WZ, Ko GN, Zhang LD, Yan WW. Clozapine in China: a review and preview of US/PRC collaboration. Psychopharmacology 1989;99(Suppl):87-91. [0033-3158: (Print); MEDLINE: Potter 1989]5772327
47. Zhang L, Xu Y. A comparison study on treatment effect of clozapine, chlorpromazine and the combination of clozapine and chlorpromazine in schizophrenia. Journal of Nervous and Mental Disease 1989; Vol. 5, issue 5:306-8. [MEDLINE: Zhang 1989]5772328
48. Cha C, Hui G, Quing G. Evaluation of therapeutic effect with chlorpromazine and clozapine for treatment of schizophrenia. Xinxiang Med Stud 1999;16:311-6. 5772330
49. Shafti SS. Augmentation of olanzapine by fluphenazine decanoate in poorly responsive schizophrenia. Clinical Schizophrenia and Related Psychoses 2009;3(2):97-102. [DOI: 10.3371/CSRP.3.2.4]5772332
50. Mossaheb N, Sacher J, Wiesegger G, Klein N, Spindelegger C, Asenbaum S, et al. Haloperidol in combination with clozapine in treatment-refractory patients with schizophrenia. European Neuropsychopharmacology 2006;16(suppl 4):416. [DOI: 10.1016/S0924-977X(06)70524-7]5772334
51. Lin CH, Kuo CC, Chou LS, Chen YH, Chen CC, Huang KH, et al. A randomized, double-blind comparison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia. Journal of Clinical Psychopharmacology 2010;30(5):518-25. [DOI: 10.1097/JCP.0b013e3181f28dff]5772336
52. Higashima M, Takeda T, Nagasawa T, Hirao N, Oka T, Nakamura M, et al. Combined therapy with low-potency neuroleptic levomepromazine as an adjunct to haloperidol for agitated patients with acute exacerbation of schizophrenia. European Psychiatry 2004;19(6):380-1. [0924-9338: (Print); DOI: 10.1016/j.eurpsy.2004.07.001; Higashima 2004]5772338
53. Hatta K, Otachi T, Fujita K, Morikawa F, Ito S, Tomiyama H, et al. Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia. Schizophrenia Research 2014;158(1-3):213-22. [DOI: 10.1016/j.schres.2014.07.015]5772340
54. Hatta K, Otachi T, Sudo Y, Kuga H, Takebayashi H, Hayashi H, et al. A comparison between augmentation with olanzapine and increased risperidone dose in acute schizophrenia patients showing early non-response to risperidone. Psychiatry Research 2012;198(2):194-201. [DOI: 10.1016/j.psychres.2012.01.006]5772342
55. Repo-Tiihonen E, Hallikainen T, Kivisto P, Tiihonen J. Antipsychotic polypharmacy in clozapine resistant schizophrenia: a randomized controlled trial of tapering antipsychotic co-treatment. Mental Illness 2012; Vol. 4:1-4. [DOI: 10.4081/mi.2012.e1]5772344
56. Yagi G. A double-blind controlled study on the usefulness of carpipramine-chlorpromazine combination in the pharmacotherapy of chronic schizophrenic patients. Clincal Evaluation 1976; Vol. 3:351-403. [MEDLINE: Yagi 1976]5772346
57. Bergmann M, Golembo S, Friedman JI, Trammel-Fisher A, Siever LJ. Pimozide augmentation of clozapine in schizophrenia. www.clinicaltrials.gov/ct2/show/NCT00158223?term=NCT00158223&rank=1 (first received 7 September 2005). [MEDLINE: Bergmann 2005]5772348
58. Friedman JI, Lindenmayer JP, Alcantara F, Bowler S, Parak M, White L, et al. Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy. Neuropsychopharmacology 2011;36(6):1289-95. [DOI: 10.1038/npp.2011.14]5772349
59. Gunduz-Bruce H. Efficacy of pimozide augmentation for clozapine partial response. www.clinicaltrials.gov/ct2/show/NCT00374244?term=Efficacy+of+pimozide+augmentation+for+clozapine+partial+response&rank=1 (first received 7 September 2006). [MEDLINE: Gunduz-Bruce 2006]5772352
60. Gunduz-Bruce H. Pimozide for Schizophrenia. Stanley Foundation Research Programs 2009. [MEDLINE: Gunduz-Bruce 2006]5772353
61. Gunduz-Bruce H, Oliver S, Gueorguieva R, Forselius-Bielen K, D'Souza DC, Zimolo Z, et al. Efficacy of pimozide augmentation for clozapine partial responders with schizophrenia. Schizophrenia Research 2013;143(2):344-7. [DOI: 10.1016/j.schres.2012.11.008]5772351
62. Jia Z, Zhang Z, Jin S. A controlled trial for comparing clozapine combined with pipothiazine palmitate to clozapine alone in the treatment of negative symptoms in schizophrenic patients. Herald of Medicine 2000;19:142-3. 5772355
63. Ni J, Jang L, Hong X. Therapeutic effects of clozapine, risperidone and their combination in the treatment of schizophrenia. Health Psychology 2001;3:181-2. 5772357
64. Peng H, Kuang Y, Huang X. A control study of risperidone in combination with clozapine in treating refractory schizophrenia. Journal of Modern Clinical Medical Bioengineering 2001;7(2):100-2. [MEDLINE: Peng 2001]5772359
65. Xin X, Du B, Zeng Z. A controlled clinical study of risperidone and low dose of clozapine in treating schizophrenia. Herald of Medicine 2001;20:501-2. 5772361
66. Akdede BB, Anil Yagcioglu AE, Alptekin K, Turgut TI, Tumuklu M, Yazici MK, et al. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. Journal of Clinical Psychiatry 2006;67(12):1912-9. [1555-2101: (Electronic); DOI: 10.4088/JCP.v67n1211; MEDLINE: Anil Yagcioglu 2005]5772363
67. Anil E. Risperidone augmented with clozapine for schizophrenia. Stanley Foundation Research Programs 2009. [MEDLINE: Anil Yagcioglu 2005]5772364
68. Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, Tumuklu M, Yazici MK, Alptekin K, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. Journal of Clinical Psychiatry 2005; Vol. 66, issue 1:63-72. [0160-6689: (Print); DOI: 10.4088/JCP.v66n0109; MEDLINE: Anil Yagcioglu 2005]5772365
69. Yagcioglu AEA, Akdede BBK, Turgut TI, Tumuklu M, Yazici MK, Alptekin K, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. 24th Congress of the Collegium Internationale Neuro-Psychopharmacologicum (CINP); 2004 Jun 20-24; Paris, France. 2004:63-72. [MEDLINE: Yagcioglu 2004]5772366
70. Josiassen RC, Joseph A, Kohegyi E, Stokes S, Dadvand M, Paing WW, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. 9th International Congress on Schizophrenia Research; 2003 Mar 29-Apr 2; Colorado Springs, CO. 2003:130-6. [MEDLINE: Josiassen 2003]5772369
71. Josiassen RC, Joseph A, Kohegyi E, Stokes S, Dadvand M, Paing WW, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. American Journal of Psychiatry 2005;162(1):130-6. [0002-953X: (Print); DOI: 10.1176/appi.ajp.162.1.130; MEDLINE: Josiassen 2005]5772368
72. Gerson SL. Clozapine alone versus clozapine and risperidone for refractory schizophrenia. New England Journal of Medicine 2006;354(17):1846-8. [1533-4406: (Electronic); MEDLINE: Honer 2006]5772371
73. Grass G, Hellmich M, Leweke FM. Clozapine alone versus clozapine and risperidone for refractory schizophrenia. New England Journal of Medicine 2006;354(17):1846-8. [1533-4406: (Electronic); MEDLINE: Honer 2006 b2]5772372
74. Honer W. A randomized controlled trial of antipsychotic polypharmacy: clozapine plus risperidone. European Neuropsychopharmacology 2007;17(Suppl 4):S200. [DOI: 10.1016/S0924-977X(07)70237-7; MEDLINE: Honer 2006 b6]5772373
75. Honer W. International study of improving treatment for the most severely ill with schizophrenia. www.clinicaltrials.gov/ct2/show/NCT00272584?term=NCT00272584&rank=1 (first received 3 January 2006). [MEDLINE: Honer 2006 a]5772374
76. Honer WG, Thornton AE, Chen EY, Chan RC, Wong JO, Bergmann A, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. New England Journal of Medicine 2006;354(5):472-82. [1533-4406: (Electronic); DOI: 10.1056/NEJMoa053222; MEDLINE: Honer 2006]5772375
77. Meltzer HY, Anil Yagcioglu AE, Akdede BB. Clozapine alone versus clozapine and risperidone for refractory schizophrenia. New England Journal of Medicine 2006;354(17):1846-8. [1533-4406: (Electronic); MEDLINE: Honer 2006 b3]5772376
78. Procyshyn RM, Wasan KM, Thornton AE, Barr AM, Chen EY, Pomarol-Clotet E, et al. Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. Journal of Psychiatry Neuroscience 2007;32(5):331-8. [1180-4882: (Print); MEDLINE: Procyshyn 2007]5772377
79. Freudenreich O. Risperidone added to clozapine for schizophrenia. Stanley Foundation Research Programs 2009. [Walsh 2006 b1]5772380
80. Freudenreich O, Henderson DC, Walsh JP, Culhane MA, Goff DC. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophrenia Research 2007;92(1-3):90-4. [0920-9964: (Print); DOI: 10.1016/j.schres.2006.12.030; Walsh 2006 b2]5772379
81. Walsh JP, Freudenreich O, Goff DC. Risperidone augmentation in patients with schizophrenia partially responsive to clozapine. www.clinicaltrials.gov/ct2/show/NCT00289861?term=NCT00289861&rank=1 (first received 8 February 2006). [MEDLINE: Walsh 2006 b]5772381
82. Nielsen J, Emborg C, Gydesen S, Dybbro J, Aagaard J, Haderup K, et al. Augmenting clozapine with sertindole: a double-blind, randomized, placebo-controlled study. Journal Clincal Psychopharmacology 2012;32(2):173-8. [DOI: 10.1097/JCP.0b013e318248dfb8]5772383
83. Nielsen J, Munk-Jorgensen P. Augmenting clozapine with sertindole - a double blinded randomized placebo study. www.clinicaltrials.gov/ct2/show/NCT00345982?term=NCT00345982&rank=1 (first received 28 June 2006). [Nielsen 2006]5772384
84. Nielsen RE, Levander S, Thode D, Nielsen J. Effects of sertindole on cognition in clozapine-treated schizophrenia patients. Acta Psychiatrica Scandinavica 2012;126(1):31-9. [DOI: 10.1111/j.1600-0447.2012.01840.x]5772385
85. Shiloh R, Zemishlany Z, Aizenberg D, Radwan M, Schwartz B, Dorfman-Etrog P, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. British Journal of Psychiatry 1997;171:569-73. [0007-1250: (Print); Shiloh 1997]5772387
86. Shiloh R, Zemishlany Z, Aizenberg D, Weizman A. Sulpiride adjunction to clozapine in treatment-resistant schizophrenic patients: a preliminary case series study. European Psychiatry 1997;12(3):152-5. [0924-9338: (Print); MEDLINE: Shiloh 1997]5772388
87. Si S, Yuan C. A comparative trial of the effects of sulpiride combined with clozapine in the treatment of schizophrenia. Shandong Archives of Psychiatry 1999;12:17-20. 5772390
88. Xao H. A double-blind comparative study of the effects of sulpiride combined with clozapine in the treatment of schizophrenia. Sichuan Mental Health 1999;12:250-1. 5772392
89. Zhu Y, Zhang S, Zhang D. A controlled trial comparing chlorimipramine and sulpiride as adjunct to clozapine in the treatment of negative symptoms of schizophrenia. Journal of Clinical Psychology in Medical Settings 1999;9(4):204-5. [MEDLINE: Zhu 1999]5772394
90. Zou G, Huang Y, Zou S, Yang Y. A comparative trial of the beneficial effects of sulpiride combined with clozapine in the treatment of refractory schizophrenia. Journal of Yichun University 2003;25:94-6. 5772396
91. Kotler M, Strous RD, Reznik I, Shwartz S, Weizman A, Spivak B. Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology. International Clinical Psychopharmacology 2004;19(1):23-6. [0268-1315: (Print); MEDLINE: Kotler 2004]5772398
92. Xu B. Observation on the effect of clozapine and sulpiride on negative symptom schizophrenia patients. China Tropical Medicine 2006;6(5):806. 5772400
93. Lin CH, Wang FC, Lin SC, Huang YH, Chen CC, Lane HY. Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study. International Clinical Psychopharmacology 2013;28(5):267-74. [DOI: 10.1097/YIC.0b013e3283633a83.]5772402
94. Ahn YM, Kweon YS, Kwon JS, Min SH, Park DB, Yang MJ, et al. The study for switching methods to olanzapine in Korean schizophrenic patients treated with other antipsychotics (II): comparison of safety Journal of Korean Neuropsychiatric Association 2002;41(5):890-4. 5772404
95. Alptekin K, Akdede B, Soygur H. TRIES: An open, randomized, prospective, multicenter study, searching the best switch policy of sertindole in patients with schizophrenia. Schizophrenia Research 2012;136:S164-5. [DOI: 10.1016/s0920-9964(12)70519-4]5772406
96. Awad G, Hassan M, Loebel A, Hsu J, Pikalov A, Rajagopalan K. Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia. BMC Psychiatry 2014;14(1):53. [DOI: 10.4088/jcp.12m07992]5772408
97. Barbui C, Accordini S, Nose M, Stroup S, Purgato M, Girlanda F, et al. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care a randomized, controlled trial. Journal of Clinical Psychopharmacology 2011;31(3):266-73. [DOI: 10.1097/JCP.0b013e318219cba3.]5772410
98. Cipriani A, Accordini S, Nose M, Purgato M, Girlanda F, Tansella M, et al. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial. Journal of Clinical Psychopharmacology 2013;33(4):533-7. [DOI: 10.1097/JCP.0b013e318296884f.]5772411
99. Nose M, Accordini S, Artioli P, Barale F, Barbui C, Beneduce R, et al. Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia. Trials 2009;10(31):31. [1745-6215: (Electronic); MEDLINE: Barbui 2006]5772412
100. Cazorla P, Mackle M, Zhao J, Ha X, Szegedi A. Safety and tolerability of switching to asenapine from other antipsychotic agents: pooled results from two randomized multicenter trials in stable patients with persistent negative symptoms in schizophrenia. Neuropsychiatric Disease and Treatment 2012;8:247-57. [DOI: 10.2147/NDT.S29891]5772414
101. ChiCTR-TRC-14004854. A randomized, controlled, multi-center clinical trial to study the treatment resistant schizophrenia (TRS) in Zhejiang province. www.chictr.org.cn/showprojen.aspx?proj=4719 (first received 26 June 2014). 5772416
102. Citrome L, Kianifard F, Meng X, Winseck A, Hochfeld M, Stahl S. Discontinuations following a switch from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia: The i-fans study. Neuropsychopharmacology 2012;38(S1):S413-S4. 5772418
103. Dai J, Gao H, Sheng J. The effect of synthetical intervention to schizophrenic and hyperlipidemia patients Medical Journal of Chinese People's Health 2012;24(5):541-2. [DOI: 10.3969/j.issn.1672-0369.2012.05.011]5772420
104. Dai T, Xu L, Houzhan L, Chen R, Fan R, Zhao H, et al. Group therapy in combination with antipsychotic medication for the treatment of schizophrenia patients in recovery period Chinese Journal of Clinical Rational Drug Use 2012;5(12A):66. 5772422
105. DRKS00008018. Are antipsychotics neurotoxic or neuroprotective? A long-term comparison of two treatment strategies. drks-neu.uniklinik-freiburg.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00008018 (first received 24 April 2015). 5772424
106. Fang M, Chen H, Li LH, Wu R, Li Y, Liu L, et al. Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia. International Clinical Psychopharmacology 2012;27(2):107-13. [DOI: 0.1097/YIC.0b013e32834fc431.]5772426
107. Fleischhacker WW, Sanchez R, Perry PP, Jin N, Peters-Strickland T, Johnson BR, et al. Aripiprazole once-monthly for the treatment of schizophrenia: A double-blind, randomized, non-inferiority study versus oral aripiprazole. Neuropsychopharmacology 2012;38(S1):S339. 5772428
108. Fleischhacker WW, Sanchez R, Johnson B, Jin N, Forbes RA, McQuade R, et al. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. International Clinical Psychopharmacology 2013;28:171-6. [DOI: 10.1097/YIC.0b013e3283615dba]5772430
109. Goff DC, Lamberti JS, Leon AC, Green MF, Miller AL, Patel J, et al. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology 2008;33(3):465-72. [0893-133X: (Print); DOI: 10.1038/sj.npp.1301444; MEDLINE: Goff 2008]5772432
110. Henderson DC, Fan X, Copeland PM, Sharma B, Borba CP, Boxill R, et al. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. Joural of Clinical Psychopharmacology 2009;29(2):165-9. [1533-712X: (Electronic); DOI: 10.1097/JCP.0b013e31819a8dbe; MEDLINE: Henderson 2009 c]5772434
111. Hwang TJ, Lo WM, Chan HY, Lin CF, Hsieh MH, Liu CC, et al. Fast versus slow strategy of switching patients with schizophrenia to aripiprazole from other antipsychotics. Journal of Clinical Psychopharmacology 2015;35(6):635-44. [DOI: 10.1097/JCP.0000000000000426.]5772436
112. JPRN-UMIN000011710. New Chiba Refractory Schizophrenia Treatment (CREST)-LAI study: Effectiveness of risperidone long-acting injectable for treatment-resistant schizophrenia. apps.who.int/trialsearch/Trial.aspx?TrialID=JPRN-UMIN000011710 (first received 2013). 5772438
113. JPRN-UMIN000012729. A comparison of medication adherence of blonanserin and aripiprazole in schizophrenic patients: a multicenter, randomized, open-label study. apps.who.int/trialsearch/Trial.aspx?TrialID=JPRN-UMIN000012729 (first received 2013). 5772440
114. JPRN-UMIN000017047. A randomized, open-label clinical trial on the efficacy of blonanserin and olanzapine in patients with schizophrenia and dopamine supersensitivity psychosis. apps.who.int/trialsearch/Trial.aspx?TrialID=JPRN-UMIN000017047 (first received 2015). 5772442
115. Kelly D, Fischer G, Suppes T. Divalproex extended release and placebo, lithium, or quetiapine for mania. www.clinicaltrials.gov/ct2/show/NCT00183443?term=Divalproex+extended+release+and+placebo%2C+lithium%2C+or+quetiapine+for+mania&rank=1 (first received 13 September 2005). [MEDLINE: Kelly 2005]5772444
116. Kreinin A, Novitski D, Weizman A. Amisulpiride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study. International Clinical Psychopharmacology 2006;21:99-103. 5772446
117. Kwon JS, Mittoux A, Hwang JY, Ong A, Cai ZJ, Su TP. The efficacy and safety of 12 weeks of treatment with sertindole or olanzapine in patients with chronic schizophrenia who did not respond successfully to their previous treatments: A randomized, double-blind, parallel-group, flexible-dose study. International Clinical Psychopharmacology 2012;27(6):326-35. [DOI: 10.1097/YIC.0b013e32835767a0]5772448
118. Lerner V, Libov I, Kotler M, Strous RD. Combination of "atypical" antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2004;28(1):89-98. [0278-5846: (Print); DOI: 10.1016/j.pnpbp.2003.09.024; MEDLINE: Lerner 2004]5772450
119. Li J. Liqi xingshen method for the treatment of TanQi Yujie type schizophrenia: a random parallel control study Journal of Practical Traditional Chinese Internal Medicine 2013;27(5):19-20. [DOI: 10.3969/j.issn.1671-7813.2013.05(s).84]5772452
120. Lieberman J, Farr G, Seoane F. TC-5619 as augmentation therapy to improve cognition in outpatients with cognitive dysfunction in schizophrenia. www.clinicaltrials.gov (first received 27 October 2009). [MEDLINE: Lieberman 2009]5772454
121. NCT01003379. TC-5619 as augmentation therapy to improve cognition in outpatients with cognitive dysfunction in schizophrenia. clinicaltrials.gov/ct2/show/NCT01003379 (first received 27 October 2009). [MEDLINE: Anon 2009]5772455
122. Lieberman JA, Cutler AJ, Lu K, Laszlovszky I, Migliore R, Durgam S. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose phase III, randomized, double-blind, placebo- and active-controlled trial. CNS Spectrums 2013;18(6):368. 5772457
123. Lieberman JA, Cutler AJ, Wan S, Migliore R, Ruth A, Laszlovszky I, et al. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, randomised, double-blind, placebo- and active-controlled trial. European Neuropsychopharmacology 2013;23:S477-8. 5772458
124. Lundbeck H. A prospective randomised double-blind parallel-group active-controlled cognition study of bifeprunox in schizophrenia (add-on study to studies 10199 and 10200). www.lundbecktrials.com (first accessed 2004). [MEDLINE: Lundbeck 2004]5772460
125. Lundbeck H. Efficacy study exploring the effect of Lu AE58054 as augmentation therapy in patients with schizophrenia. www.clinicaltrials.gov/ct2/show/NCT00810667?term=Efficacy+study+exploring+the+effect+of+Lu+AE58054+as+augmentation+therapy+in+patients+with+schizophrenia&rank=1 (first received 17 December 2008). [MEDLINE: Lundbeck 2008]5772462
126. Mantovani C, Labate CM, Sponholz AJ, de Azevedo Marques JM, Guapo V G, de Simone Brito dos Santos ME, et al. Are low doses of antipsychotics effective in the management of psychomotor agitation? A randomized, rated-blind trial of four intramuscular interventions. Journal of Clinical Psychopharmacology 2013;33:306-12. 5772464
127. Johnson, Johnson. Randomized, Double-blind, Placebo- and Active-controlled Parallel Group, Dose-response Study to Evaluate the Efficacy and Safety of 3 Fixed Dosages of Paliperidone Extended Release (6, 9, and 12 mg/Day) and Olanzapine (10 mg/Day) With Open-label Extension in Treatment of Schizophrenia. www.clinicaltrials.gov/ct2/show/NCT00078039?term=Randomized%2C+Double-blind%2C+Placebo-+and+Active-controlled+Parallel+Group%2C+Dose-response+Study+to+Evaluate+the+Efficacy+and+Safety+of+3+Fixed+Dosages+of+Paliperidone+Extended+Release&rank=1 (first received 17 February 2004). 5772466
128. Meltzer H, Bobo W, Nuamah I, Lane R, Hough D, Kramer M, et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. Journal Of Clinical Psychiatry 2008;69(5):817-29. 5772467
129. Meltzer HY, Elkis H, Vanover K, Weiner DM, Van Kammen DP, Peters P, et al. Pimavanserin, a selective serotonin (5-ht)2a-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day. Schizophrenia Research 2012;141:144-52. [DOI: 10.1016/j.schres.2012.07.029.; MEDLINE: 22954754]5772469
130. Shi S. Antipsychotic medication combined psychological intervention for the treatment of patients with schizophrenia Chinese Medicine Guide 2013;11(4):505-6. 5772471
131. Mir A, Shivakumar K, Williamson RJ, McAllister V, O'Keane V, Aitchison KJ. Change in sexual dysfunction with aripiprazole: A switching or add-on study. Journal of Psychopharmacology 2008;22(3):244-53. [DOI: 10.1177/0269881107082901]5772473
132. Mythri SV, Tharyan P, Sunder S, Kattula D, Kirubakaran R, Adams CE. Rapid tranquillization of violent or agitated patients in a psychiatric emergency setting: Pragmatic, randomized, allocation concealed, participant and assessor blinded trial of intramuscular zuclopenthixol acetate versus intramuscular haloperidol plus promethazine [A comparative study of the effects of an intramuscular injection of zuclopenthixol acetate versus an intramuscular injection of a combination of haloperidol plus promethazine in people with violence or agitation presenting to a psychiatric hospital as an emergency]. Study Protocol (as supplied 2013). 5772475
133. NCT01003379. TC-5619 as augmentation therapy to improve cognition in outpatients with cognitive dysfunction in schizophrenia. clinicaltrials.gov/ct2/show/record/NCT01003379 (first received 27 October 2009). 5772477
134. NCT01234779. A study of ro4917838 in patients with acute exacerbation of schizophrenia. clinicaltrials.gov/show/NCT01234779 (first received 3 November 2010). 5772479
135. NCT01939548. A 12-week, randomized, phase 2, double-blind, parallel-group study of two dose levels of PF-02545920 compared to placebo in the adjunctive treatment of outpatients with sub-optimally controlled symptoms of schizophrenia. clinicaltrials.gov/show/NCT01939548 (first received 9 August 2013). 5772481
136. NCT02477670. Efficacy, safety, and tolerability of AVP-786 for the treatment of residual schizophrenia. clinicaltrials.gov/show/NCT02477670 (first received 18 June 2015). 5772483
137. Pfizer. A study of PF-03463275 as add-on therapy in outpatients with persistent negative symptoms of schizophrenia. clinicaltrials.gov/ct2/show/NCT00977522?term=A+study+of+PF-03463275+as+add-on+therapy+in+outpatients+with+persistent+negative+symptoms+of+schizophrenia&rank=1 (first received 14 September 2009). [MEDLINE: Pfizer 2009]5772485
138. Ruiz-Doblado S, Baena-Baldomero A, Esparrago-Llorca G. Pharmacological augmentation strategies in clozapine-resistant schizophrenia: Overcoming the resistance. Psiquiatria Biologica 2010;17(3):96-101. [DOI: 10.1016/j.psiq.2010.07.002]5772487
139. Rupnow M, Greenspan A, Kosik-Gonzalez C, Bossie C, Zhu Y, Gharabawi G, et al. Polypharmacy in schizophrenia: data from a randomized, double-blind study. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta, Georgia, USA. 2005. [MEDLINE: Rupnow 2005]5772489
140. Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L. Comparative efficacy and safety of ziprasidone and clozapine in treatment refractory schizophrenic patients: results of a randomized, double-blind, 18-week trial. 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland 2006. [MEDLINE: Sacchetti 2006]5772491
141. Semenikhin DG, Kuchaeva AV, Karpov AM, Mikhailova EB, Murav'eva AV. Additional possibilities for correction of movement disorders induced by neuroleptics in patients with schizophrenia. Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova 2013;113(11):78-80. 5772493
142. Sofronov A, Spikina A, Savelyev A. The role of modern antipsychotics in correction of neurocognitive deficit in schizophrenia patients. European Psychiatry 2013;28:1247. [DOI: 10.1016/S0924-9338(13)76320-X]5772495
143. Spyker DA, Riesenberg RA, Cassella JV. Multiple dose pharmacokinetics of inhaled loxapine in subjects on chronic, stable antipsychotic regimens. Journal of Clinical Pharmacology 2015;55(9):985-94. [DOI: 10.1002/jcph.502]5772497
144. Stahl S, Cucchiaro J, Simonelli D, Loebel A. Long-term safety and tolerability of lurasidone in subjects with schizophrenia: results of a 6-month, open-label study. 49th Annual meeting of the Americam College of Neuropsychopharmacology; 5-9 December 2010; Miami, Florida. 2010. 5772499
145. Sukegawa T, Ito T, Hasegawa M, Mizuno Y, Inagaki A, Sakamoto H, et al. A randomized controlled trial on the dose reduction and simplification for polypharmacy of antipsychotics. Tottori Journal of Clinical Research 2008;1(1):169-81. 5772501
146. Sukegawa T, Inagaki A, Yamanouchi Y, Inada T, Yoshio T, Yoshimura R, et al. Study protocol: safety correction of high dose antipsychotic polypharmacy in Japan. BMC Psychiatry 2014;14(1):103. [DOI: 10.1186/1471-244X-14-103]5772503
147. Hirano J, Watanabe K, Suzuki T, Uchida H, et al. An open-label study of algorithm-based treatment versus treatment-as-usual for patients with schizophrenia. Neuropsychiatric Disease and Treatment 2013;9:1553-64. [DOI: 10.2147/ndt.s46108]5772505
148. UMIN000004931. An intervention study of optimizing algorism-based pharmacological treatment for schizophrenia. www.umin.ac.jp/ctr/index.htm (first received 22 January 2011). 5772506
149. Wang W, Chen H, Zhao L. Antipsychotic medication combined with acupuncture therapy for the treatment of schizophrenia Medical Journal of Chinese People's Health 2013;25(10):63-4. [DOI: 10.3969/j.issn.1672-0369.2013.10.043]5772508
150. Weiden PJ, Citrome L, Glick ID, Alva G, Winseck A, Kianifard F, et al. Initial 2-week outcomes following 2 methods of switching to iloperidone from risperidone in patients with schizophrenia. CNS Spectrums 2013;18(6):348. 5772510
151. Wilson WH. Open clozapine treatment following a controlled clinical trial of lithium augmentation of haloperidol for refractory schizophrenia. Lithium 1994;5(2):113-4. 5772512
152. Winseck A, Glick ID, Weiden PJ, Citrome L, Alva G, Kianifard F, et al. Initial 2-week outcomes following 2 methods of switching to iloperidone from aripiprazole in patients with schizophrenia. CNS Spectrums 2013;18(6):362-3. 5772514
153. Wu L. A control study of risperidone and clozapine combination for the treatment of refractory schizophrenia. Health Psychology 2002;10:135-7. 5772516
154. Clinical study of aripiprazole combined with ziprasidone for schizophrenia 2015;22(1):145. 5772518
155. Xia SY, Zhang YR, Yu H, Meng X, Zhang P, Liu J. Treatment of antipsychotic drug-induced phlegm dampness type amenorrhea by Wuji Powder and a small dose aripiprazole: a clinical study. Chinese Journal of Integrated Traditional and Western Medicine 2014;34(12):1440-3. 5772520
156. Xu. Clinical observation of sertraline combined with sulpiride for first onset schizophrenia 2008;30(6):542-3. 5772522
157. UMIN000004511. The clinical study to correct multiple and large amount of administering to antipsychotic safely and effectively. www.umin.ac.jp/ctr/index.htm (first received 10 November 2010). 5772524
158. Yamanouchi Y, Sukegawa T, Inagaki A, Inada T, Yoshio T, Yoshimura R, et al. Evaluation of the individual safe correction of antipsychotic agent polypharmacy in Japanese patients with chronic schizophrenia: validation of safe corrections for antipsychotic polypharmacy and the high-dose method. International Journal of Neuropsychopharmacology 2015;18:5. [DOI: http://dx.doi.org/10.1093/ijnp/pyu016]5772525
159. Yue H, Song L, Xu Y. A comparative trial of risperidone in the treatment of schizophrenia over two years. Shangai Archive of Psychiatry 2004;16:165-7. 5772527
160. Zhang L, Wang J, Zhang Z. Shugan-Jieyu capsule combined with antipsychotics for the treatment of negative symptoms of schizophrenia Zhejiang Journal of Traditional Chinese Medicine 2012;10(4):228-9. 5772529
161. Zhang B, Chang L. Venlafaxine combined antipsychotics in the treatment of negative symptoms of schizophrenia Shanxi Medical Journal 2013;42(6):685-6. 5772531
162. Kuwilsky A, Krumm B, Englisch S, Dressing H, Zink M. Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone. Pharmacopsychiatry 2010;43(6):216-20. 5772533
163. Zink M. Clozapine-augmentation with ziprasidone or risperidone, a randomized, prospective trial. www.clinicaltrials.gov (first received 15 September 2005). [MEDLINE: Zink 2005_a]5772535
164. Zink M, Kuwilsky A, Krumm B, Dressing H. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial. Journal of Psychopharmacology 2009;23(3):305-14. [0269-8811: (Print); MEDLINE: Zinc 2009]5772534
165. NCT01450514. Proof-of-concept study of pipamperone 15mg added to stable risperidone or paliperidone treatment in chronic schizophrenic and schizoaffective patients with residual symptoms: a Phase I/IIa, randomized, double-blind, placebo-controlled trial of 7 weeks. clinicaltrials.gov/show/NCT01450514 (first received 7 October 2011). 5772537
166. Xu L, Ji Jue H, Shi H. A control study of aripiprazole in the treatment of hyperprolactinemia by antipsychotics origin Chinese Journal of Behavioral Medical Science 2006;15(8):718-20. 5772539
167. Han X, Yuan YB, Yu X. The Chinese first-episode schizophrenia trial: Background and study design East Asian Archives of Psychiatry 2014;24:169-73. 5772541
168. Yuan Y, Yang F, Lu Z, Wang CY, Deng H, Zhao J, et al. Effectiveness of three atypical antipsychotic-initiated treatments in chinese first-episode schizophrenia: An open randomized clinical trial. Schizophrenia Research 2014;153(Suppl. 1):S218. [DOI: 10.1016/S0920-9964(14)70628-0]5772542
169. CTRI-02-003397. Efficacy of Aripiprazole adjunctive treatment on body weight, metabolic parameters, clinical efficacy, and adverse events in people with psychotic disorders on treatment with Clozapine. A randomized, double-blind, placebo-controlled trial. www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=5862 (first received 14 February 2013). 5772544
170. ISRCTN68824876. Amisulpiride augmentation in clozapine-unresponsive schizophrenia. www.controlled-trials.com/ISRCTN68824876 (first received 2 March 2010). 5772546
171. NCT01246232. Amisulpiride augmentation in clozapine-unresponsive schizophrenia. clinicaltrials.gov/ct2/show/NCT01246232 (first received 22 November 2010). 5772547
172. DRKS00003603. A randomized double-blind controlled trial to assess the benefits of olanzapine and amisulpiride combination treatment in acutely ill schizophrenia patients - COMBINE. ichgcp.net/clinical-trials-registry/NCT01609153 (first received 1 June 2012). 5772549
173. NCT01609153. A randomized double-blind controlled trial to assess the benefits of olanzapine and amisulpride combination treatment in acutely ill schizophrenia patients - COMBINE. http://ClinicalTrials.gov/show/NCT01609153 (first received 23 May 2012). 5772550
174. Schmidt-Kraepelin C. A RCT to assess the benefits of olanzapine and amisulpride combination treatment (COMBINE): design and methods. European Archives of Psychiatry and Clinical Neuroscience 2013;263(Suppl. 1):S15-6. 5772551
175. Ahmed I, Soares KV, Seifas R, Adams CE. Randomized controlled trials in Archives of General Psychiatry (1959-1995): a prevalence study. Archives of General Psychiatry 1998;55(8):754-5. [PUBMED: 9707389]
176. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
177. Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS). Iowa City, Iowa: University of Iowa, 1983.
178. Andreasen NC. The Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, Iowa: University of Iowa, 1984.
179. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington DC: American Psychiatric Publishing Inc., 2000.
180. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. Washington, DC: American Psychiatric Publishing, 2013. [DOI: 10.1176/appi.books.9780890425596]
181. Barber S, Olotu U, Corsi M, Cipriani A. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. Cochrane Database of Systematic Reviews 2017, Issue 3. [DOI: 10.1002/14651858.CD006324.pub3; CD006324]
182. Barnes TRE. A rating scale for drug-induced akathisia. British Journal of Psychiatry 1989;154:672-6.
183. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996;276(8):637-9. [PUBMED: 8773637]
184. Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
185. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie 1999;54(4):405-11. [PUBMED: 10667106]
186. [No authors listed]. Combination and high-dose atypical antipsychotic therapy in patients with schizophrenia: systematic review. Canadian Agency for Drugs and Technologies in Health overviews 2012;2(3):e2301. [PUBMED: 23002379]
187. Centorrino F, Fogarty KV, Sani G, Salvatore P, Cincotta SL, Hennen J, et al. Use of combinations of antipsychotics: McLean Hospital inpatients, 2002. Human Psychopharmacology 2005;20(7):485-92. [DOI: 10.1002/hup.719]
188. Chouinard G, Ross-Chouinard A, Annable L, Jones BD. The extrapyramidal symptom rating scale. Canadian Journal of Neurological Sciences 1980;7:233.
189. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: A meta-analysis of randomized controlled trials. Schizophrenia Bulletin 2009;35(2):443-57. [DOI: 10.1093/schbul/sbn018]
190. Deeks J. Issues in the selection for meta-analyses of binary data. 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.
191. Deeks JJ, Higgins JPT, Altman DG, editor(s). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
192. Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623-9.
193. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
194. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
195. Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
196. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The Global Assessment Scale: A procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry 1976;33(6):766-71.
197. Freudenreich O, Goff D. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatrica Scandinavica 2002;106:320-30. [DOI: 10.1034/j.1600-0447.2002.01331.x]
198. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7-10.
199. Gaebel W, Weinmann S, Sartorius N, Rutz W, McIntyre JS. Schizophrenia practice guidelines: international survey and comparison. British Journal of Psychiatry 2005;187(3):248-55. [DOI: 10.1192/bjp.187.3.248]
200. Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU. Prevalence and correlates of antipsychotic polypharmacy: A systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophrenia Research 2012;138(1):18-28. [DOI: 10.1016/j.schres.2012.03.018]
201. Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. Journal of Clinical Psychiatry 2004;65(10):1377-88. [DOI: 10.4088/JCP.v65n1013]
202. Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. American Journal of Psychiatry 2010;167(6):686-93. [DOI: 10.1176/appi.ajp.2009.09060802]
203. Gründer G, Hippius H, Carlsson A. The 'atypicality' of antipsychotics: a concept re-examined and re-defined. Nature Reviews Drug Discovery 2009;8(3):197-202. [DOI: 10.1038/nrd2806]
204. Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
205. Guy U. Early Clinical Drug Evaluation (ECDEU) Assessment Manual for Psychopharmacology. National Institute of Mental Health, 1976.
206. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World Journal of Biological Psychiatry 2012;13(5):318-78. [DOI: 10.3109/15622975.2012.696143]
207. Heinrich DW, Hanlon TE, Carpenter WT. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 1984;10:388-98.
208. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
209. Higgins JPT, Green S, editor(s). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
210. Higgins JPT, Altman DG, Sterne JAC, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
211. Jainen, Juola P, Hirvonen N, McGrath J, Saha S, Isohanni M, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophrenia Bulletin 2012;39(6):1296-306. [DOI: 10.1093/schbul/sbs130]
212. Kapur S, Remington G. Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biological Psychiatry 2001;50(11):873-83. [DOI: 10.1016/S0006-3223(01)01251-3]
213. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda (NY): Multi-Health Systems, 1986.
214. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987;13(2):261-76.
215. Kim JH, Jung HD, Kang UG, Jeong SH, Ahn YM, Byun HJ, et al. Metric characteristics of the drug-induced extrapyramidal symptoms scale (DIEPSS): A practical combined rating scale for drug-induced movement disorders. Movement Disorders 2002;17:1354-9.
216. Kirkpatrick B, Fenton WS, Carpenter WT, Marder SR. The NIMH-MATRICS consensus statement on negative symptom. Schizophrenia bulletin 2006;32(2):214-9. [DOI: 10.1093/schbul/sbj053]
217. Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry 2006;59(11):1001-5. [PUBMED: 16905632]
218. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2-3):231-8. [PUBMED: 15982856]
219. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366-71. [PUBMED: 16199797]
220. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and across-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica 1987;334(Suppl.):1-100.
221. Magalhaes PVS, Dean O, Andreazza AC, Berk M, Kapczinski F. Antioxidant treatments for schizophrenia. Cochrane Database of Systematic Reviews 2016, Issue 2. [DOI: 10.1002/14651858.CD008919.pub2]
222. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
223. McGrath J, Saha S, Welham J. Schizophrenia: A concise overview of incidence, prevalence, and mortality. Epidemiologic Reviews 2008;30(1):67-76. [DOI: 10.1093/epirev/mxn001]
224. Meader N, King K, Llewellyn A, Norman G, Brown J, Rodgers M, et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Systematic Reviews 2014;3:82. [DOI: 10.1186/2046-4053-3-82]
225. Meltzer HY, Kostakoglu AE. Combining antipsychotics: is there evidence for efficacy?. Psychiatric Times 2000;17:25-34.
226. Meng M, Li W, Zhang S, Wang HY, Sheng JH, Wang J, et al. Using aripiprazole to reduce antipsychotic-induced hyperprolactinemia: meta-analysis of currently available randomized controlled trials. Shanghai Archives of Psychiatry 2015;27(1):4-17. [DOI: 10.11919/j.issn.1002-0829.215014]
227. Misawa F, Shimizu K, Fujii Y, Miyata R, Koshiishi F, Kobayashi M, et al. Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study. BMC Psychiatry 2011;11(1):118. [DOI: 10.1186/1471-244X-11-118]
228. Naber D. A self-rating to measure subjective effects of neuroleptic drugs. Relationships to objective psychopathology, quality of life, compliance and other clinical variables. International Clinical Psychopharmacology 1995;10:133-8.
229. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:790-812.
230. Paton C, Barnes TR, Cavanagh MR, Taylor D, Lelliott P. High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by prn prescribing. British Journal of Psychiatry 2008;192(6):435-9. [DOI: 10.1192/bjp.bp.107.042895]
231. Rupnow MF, Greenspan A, Gharabawi GM, Kosik-Gonzalez C, Zhu Y, Stahl SM. Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder. Current Medical Research and Opinion 2007;23(11):2815-22. [DOI: 10.1185/030079907X233359]
232. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
233. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
234. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica 1970;(Suppl 212):11-9.
235. Sommer IE, Begemann MJ, Temmerman A, Leucht S. Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophrenia Bulletin 2012;38(5):1003-11. [PUBMED: 21422107]
236. Sterne JAC, Egger M, Moher D, editor(s). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
237. Taylor DM, Smith L. Augmentation of clozapine with a second antipsychotic--a meta-analysis of randomized, placebo-controlled studies. Acta Psychiatrica Scandinavica 2009;119(6):419-25. [PUBMED: 19245679]
238. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75.
239. Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. British Journal of Psychiatry 1998;173:325-9.
240. Ware JE, Sherbourne CD. The MOS 36-Item short-form health survey (SF-36®): I. conceptual framework and item selection. Medical Care 1992;30(6):473-83.
241. Weiden PJ, Casey DE. "Polypharmacy": Combining antipsychotic medications in the treatment of schizophrenia. Journal of Practical Psychiatry and Behavioral Health 1999;5:229-33.
242. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.
243. Maayan N, Soares-Weiser K, Xia J, Adams CE. Antipsychotic combinations for schizophrenia. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD009005]